Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Possible Biomarkers for Cancer Immunotherapy.

Otoshi T, Nagano T, Tachihara M, Nishimura Y.

Cancers (Basel). 2019 Jul 3;11(7). pii: E935. doi: 10.3390/cancers11070935. Review.

2.

The clinical utility of tumor mutational burden in non-small cell lung cancer.

Greillier L, Tomasini P, Barlesi F.

Transl Lung Cancer Res. 2018 Dec;7(6):639-646. doi: 10.21037/tlcr.2018.10.08. Review.

3.

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.

Zhao P, Li L, Jiang X, Li Q.

J Hematol Oncol. 2019 May 31;12(1):54. doi: 10.1186/s13045-019-0738-1. Review.

4.

PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.

Xia L, Liu Y, Wang Y.

Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.

5.

Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy.

Hendriks LE, Rouleau E, Besse B.

Transl Lung Cancer Res. 2018 Dec;7(6):647-660. doi: 10.21037/tlcr.2018.09.22. Review.

6.

Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors.

Nadal E, Massuti B, Dómine M, García-Campelo R, Cobo M, Felip E.

Cancer Immunol Immunother. 2019 Mar;68(3):341-352. doi: 10.1007/s00262-019-02310-2. Epub 2019 Feb 6. Review.

PMID:
30725206
7.

Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).

Yoneda K, Imanishi N, Ichiki Y, Tanaka F.

J UOEH. 2018;40(2):173-189. doi: 10.7888/juoeh.40.173. Review.

8.

Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.

Mushtaq MU, Papadas A, Pagenkopf A, Flietner E, Morrow Z, Chaudhary SG, Asimakopoulos F.

J Immunother Cancer. 2018 Jul 3;6(1):65. doi: 10.1186/s40425-018-0376-0. Review.

9.

Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.

Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y, Lin D, Gao Q, Zhou H, Liao W, Yao H.

JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.

10.

Gut microbiome modulates efficacy of immune checkpoint inhibitors.

Yi M, Yu S, Qin S, Liu Q, Xu H, Zhao W, Chu Q, Wu K.

J Hematol Oncol. 2018 Mar 27;11(1):47. doi: 10.1186/s13045-018-0592-6. Review.

11.

Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.

Meng X, Huang Z, Teng F, Xing L, Yu J.

Cancer Treat Rev. 2015 Dec;41(10):868-76. doi: 10.1016/j.ctrv.2015.11.001. Epub 2015 Nov 10. Review.

PMID:
26589760
12.

Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?

Costantini A, Takam Kamga P, Dumenil C, Chinet T, Emile JF, Giroux Leprieur E.

Cancers (Basel). 2019 Aug 29;11(9). pii: E1269. doi: 10.3390/cancers11091269. Review.

13.

Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events.

Nakamura Y.

Front Med (Lausanne). 2019 May 29;6:119. doi: 10.3389/fmed.2019.00119. eCollection 2019. Review.

14.

Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors.

Zhu Y, Zhao F, Li Z, Yu J.

Cancer Manag Res. 2018 Aug 7;10:2475-2488. doi: 10.2147/CMAR.S167400. eCollection 2018. Review.

15.

Biomarqueurs prédictifs de réponse aux inhibiteurs de points de contrôle immuns.

Frelau A, Pracht M, Le Sourd S, Lespagnol A, Corre R, Ménard C, Tarte K, Mosser J, Edeline J.

Bull Cancer. 2018 Dec;105 Suppl 1:S80-S91. doi: 10.1016/S0007-4551(18)30393-X. Review. French.

PMID:
30595202
16.

Novel Biomarkers for Personalized Cancer Immunotherapy.

Shindo Y, Hazama S, Tsunedomi R, Suzuki N, Nagano H.

Cancers (Basel). 2019 Aug 22;11(9). pii: E1223. doi: 10.3390/cancers11091223. Review.

17.

Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients.

Duffy MJ, Crown J.

Clin Chem. 2019 Jul 17. pii: clinchem.2019.303644. doi: 10.1373/clinchem.2019.303644. [Epub ahead of print]

PMID:
31315901
18.

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).

Jeanson A, Tomasini P, Souquet-Bressand M, Brandone N, Boucekine M, Grangeon M, Chaleat S, Khobta N, Milia J, Mhanna L, Greillier L, Biemar J, Nanni I, Ouafik L, Garcia S, Mazières J, Barlesi F, Mascaux C.

J Thorac Oncol. 2019 Jun;14(6):1095-1101. doi: 10.1016/j.jtho.2019.01.011. Epub 2019 Feb 6.

PMID:
30738221
19.

Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.

Teng F, Meng X, Kong L, Yu J.

Cancer Lett. 2018 Feb 1;414:166-173. doi: 10.1016/j.canlet.2017.11.014. Epub 2017 Nov 16. Review.

PMID:
29155348
20.

Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma.

Loo K, Daud A.

Immunotherapy. 2016 Jun;8(7):775-84. doi: 10.2217/imt-2016-0039. Review.

PMID:
27349977

Supplemental Content

Support Center